SCHEMBL26683281

SCHEMBL26683281

Clc1cc2sc(N3CCNCC3)cc2nn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BPTF Q12830 1/20 0.44
▸ ADRB1 P08588 5/20 0.38
▸ CHRM2 P08172 1/20 0.38
▸ CHRM4 P08173 1/20 0.38
▸ CHRM1 P11229 1/20 0.38
▸ CHRM3 P20309 1/20 0.38
▸ HTR3E A5X5Y0 4/20 0.36
▸ HTR3B O95264 4/20 0.36
▸ HTR3A P46098 4/20 0.36
▸ HTR3D Q70Z44 4/20 0.36
▸ HTR3C Q8WXA8 4/20 0.36
▸ HTR2C P28335 4/20 0.36
▸ CHRNB2 P17787 3/20 0.36
▸ CHRNA4 P43681 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ HTR1A P08908 2/20 0.36
▸ CYP2C9 P11712 2/20 0.36
▸ HTR2A P28223 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26683185 0.73 PBRM1 (0.56) HTR2CCYP1A2CYP2C19KDM4ESCN4A
SCHEMBL3688205 0.70 HTR2C (0.46) HTR2CALDH1A1HTR1AHTR2AKDM4E
SCHEMBL195335 0.68 BPTF (0.49) BPTFADRB1CHRM2CHRM4CHRM1
SCHEMBL195203 0.67 BPTF (0.51) BPTFADRB1CHRM2CHRM4CHRM1
SCHEMBL30282824 0.67 BPTF (0.51) BPTFADRB1CHRM2CHRM4CHRM1
SCHEMBL26683356 0.67 TDP1 (0.33) —
Hydrochloric Acid SCHEMBL23037230 0.67 BPTF (0.47) BPTFADRB1CHRM2CHRM4CHRM1
SCHEMBL8339118 0.66 BPTF (0.50) BPTFADRB1CHRM2CHRM4CHRM1
SCHEMBL30658007 0.66 BPTF (0.43) BPTFADRB1CHRM2CHRM4CHRM1
SCHEMBL26653837 0.66 BPTF (0.43) BPTFADRB1CHRM2CHRM4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304596-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC (US) 2025-10-02 — — US disclosed
EP-4522277-A1 PYRAZINE DERIVATIVES AND USES THEREOF Foghorn Therapeutics Inc. (US) 2025-03-19 — — EP disclosed
WO-2023220137-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed
WO-2023220137-A1 PYRAZINE DERIVATIVES AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304596-A1 PYRAZINE DERIVATIVES AND USES THEREOF VHL, BRCA1, SF3B5 BPTF 175/4885ADRB1 3248/4885CHRM2 4685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback